Abstract:AIM:Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.METHODS:Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.RESULTS:CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).CONCLUSION:CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.

Application of ntPCR-RFLP assay to detect adefovir dipivoxil resistance-associated mutation in hepatitis B virus:rtN236T mutation

Application of Nest PCR-RFLP in the Detection of Adefovir Dipivoxil Resistance-Associated Mutation in Hepatitis B Virus

Application of PCR-RFLP in detection of adefovir dipivoxil resistance-associated mutations in hepatitis B virus

Reverse Line Probe Hybridization Assay for Detection of Lamivudine-Resistant Chronic Hepatitis B Virus

Rte218g, a Novel Hepatitis B Virus Mutation with Resistance to Adefovir Dipivoxil in Patients with Chronic Hepatitis B

Adefovir resistance related mutations in reverse transcription region and their effect on the biological features of hepatitis B virus

Application of PCR‐LDR‐nucleic Acid Detection Strip in Detection of YMDD Mutation in Hepatitis B Patients Treated with Lamivudine

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

The Construction of HBV Strains with Rtn236t and Rta181v/t Mutations Associated with Resistance to Adefovir and Its Viral Characteristics

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

To establish a new and simple method of genotyping of hepatitis B virus by PCR-RFLP to analysis on S region

rtA181S mutation in the reverse-transcriptase domain of HBV is associated with adefovir dipivoxil resistance

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

P.038 Differences of Ymdd Mutational Patterns, Pre-Core/core Promoter Mutations, Serum Viral Loads in Lamivudine-Resistant Hepatitis B Genotypes B and C

Establishment and application of a novel PCR assay for amplifying the full-length reverse transcriptase gene region of genotypes A～D of hepatitis B virus

Impact of I233V mutation in the hepatitis B virus reverse transcriptase domain on adefovir resistance

Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs

Evaluation of the Performance of a DNA Microarray Method for Detecting HBV Mutations Conferring Antiviral Resistance to Lamivudine and Adefovir

New Universal Primers for Genotyping and Resistance Detection of Low HBV DNA Levels.

Novel rtM204 Mutations in HBV Polymerase Confer Reduced Susceptibility to Adefovir and Tenofovir

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.